Roughly eight percent of the human genome is old virus - retroviral DNA that integrated into a distant ancestor and never left. Most of it is silent in healthy tissue. Some of it wakes up in cancer cells, senescent cells, and neurodegenerative lesions. J. Robert Coleman runs a biotech built on the premise that this reawakening is a drug target.
The company is HERVolution Therapeutics, headquartered on Nordre Fasanvej in Frederiksberg, Denmark. Coleman is Chairman and CEO, working from New York. In December 2024 the company closed an $11.7 million Series A - modest by biotech standards, precise by target-choice standards. The money buys a chance to prove that human endogenous retroviruses - HERVs - can be turned into shared antigens the immune system can be taught to attack.
The Target Nobody Was Using
The dark genome - the 98 percent of human DNA that does not code for classical proteins - has spent most of the last fifty years on scientific parole. Non-coding. Junk. Unreadable. Human endogenous retroviruses are a specific fraction of this territory: viral sequences deposited over millions of years of infections in the germline. They copy-pasted themselves in, mutated, went dormant. Selection did not bother to delete them.
Then, in the last decade, sequencing got cheap enough that researchers noticed HERV transcripts flaring in tumors and in aging cells. In prostate, pancreatic, and breast cancers. In senescent cells that refuse to die. In multiple sclerosis and amyotrophic lateral sclerosis lesions. Same viral shrapnel, different diseases.
HERVolution's bet, in one sentence: if HERVs are expressed in diseased cells and absent in healthy ones, they are a shared antigen. Shared antigens are what oncology drug developers have wanted for a decade - a target that shows up across many patients' tumors, big enough that the immune system, properly instructed, will find it.
We have the ideal blend for an emerging biotech - innovative, differentiated, and proprietary science combined with a dedicated team.
The instruction happens through a proprietary vector platform - adenoviral, mRNA, and virus-like particle formats that present engineered HERV antigens to the immune system. The pipeline extends into prostate, pancreatic, and breast oncology, and into senescent-cell and neurodegenerative programs. One target family, three franchises.
Codagenix, Before
Coleman did not come to HERVolution to learn immunology. He co-founded Codagenix out of Stony Brook University around 2011, alongside his PhD advisor Eckard Wimmer - the virologist whose lab, in 2002, assembled a live poliovirus from mail-ordered DNA. That paper is the founding document of a small industry that treats viral genomes as engineering substrates.
Codagenix industrialized one particular trick from that lineage: codon-pair deoptimization. Take a virus, rewrite thousands of synonymous codons so the protein sequence is unchanged but the underlying RNA is unfavorable to the host translation machinery. The virus replicates weakly. It still trains the immune system. You get a live-attenuated vaccine designed on a laptop.
Under Coleman the company brought three vaccines into clinical trials. Its intranasal COVID-19 vaccine, CoviLiv, was picked up by the World Health Organization's Solidarity Trial Vaccines program. Coleman raised up to $498 million across public and private financings, went on the Jefferies Healthcare Conference circuit, and by 2023 the platform he had spent a decade building was mature enough that he could hand it off.
As a live attenuated vaccine, COVI-VAC has the potential to provide a broader immune response in comparison to other COVID-19 vaccines that target only a portion of the virus.
What Changes When You Change Your Virus
The intellectual continuity is worth pausing on. At Codagenix, Coleman's opponent was an ordinary virus that had to be tamed. At HERVolution, his opponent is a virus that was already tamed millions of years ago and now needs to be revealed. Different verb, same object.
The immunology muscle - antigen engineering, vector design, adenoviral construction, cGMP manufacturing, clinical trial architecture for a novel modality - is transferable in ways that a lot of biotech pivots are not. Investors have noticed. HERVolution's total funding sits at roughly $18.5 million, and the syndicate skews toward operators who like platform companies with more than one clinical shot on goal.
One platform, three problem spaces
The Career, in Chronological Order
Details That Explain the Rest
The Sentence He Keeps Saying
Read Coleman's press releases at Codagenix and at HERVolution and you find the same rhetorical move. The lead is the modality - live-attenuated, intranasal, HERV-targeted, dark-genome-derived - and the closer is the breadth of what that modality can do. Broad immune response. Broadly applicable vaccines. Multi-disease pipeline.
Our synthetic biology platform enables us to develop potent and broadly applicable vaccines aimed at the full range of viral epitopes in their naturally occurring conformational state.
The word doing the work in every one of those sentences is broad. Coleman is a platform CEO in the sense that his companies do not sell one drug against one target - they sell a way of making drugs against a category of targets. That is a harder financing story than a lead-asset company, and Coleman has now told it twice, once at Codagenix scale and once, so far, at HERVolution scale.
What Comes Next
An $11.7 million Series A does not carry a preclinical immunotherapy company to a first pivotal readout. It buys IND-enabling work on a lead program, a proof-of-concept, and the credibility to raise a Series B on real biology. The obvious near-term milestones: nominate a lead HERV-targeted candidate, publish preclinical data in tumor models where HERV expression is well characterized (prostate cancer sits high on that list), and file with a regulator.
The less obvious milestone is investor education. HERVs are not, yet, a shorthand target class the way KRAS or PD-1 became. Coleman's job as a platform CEO is partly scientific - and partly the slow, patient work of turning a curiosity in the sequencing literature into a category label investors and pharma partners recognize on a slide.
He has done this before. Codagenix started as a story about codon pairs and ended as a story about a WHO Solidarity-Trial vaccine candidate. The next act is a story about the dark genome, told to people who have spent their careers ignoring it.